Renowned Footballer David Beckham Invests In Small Health & Wellness Firm Prenetics
Renowned Footballer David Beckham Invests In Small Health & Wellness Firm Prenetics
On Thursday, Prenetics Global Limited (NASDAQ:PRE) announced that former international footballer, entrepreneur, and philanthropist David Beckham has become a strategic investor in the business.
週四，全球貨幣公司Prenetics Global Limited（納斯達克：PRE）宣佈前國際足球運動員，企業家和慈善家David Beckham已成爲業務的戰略投資者。
Prenetics and Beckham will become co-founding partners of a new health and wellness brand, IM8, which will focus on consumer health products, with details to be announced at a later date.
Prenetics和貝克漢姆將成爲IM8，這個新的注重消費者健康產品的健康和保健品牌的共同創始夥伴。詳情將於以後公佈。
Beckham said, "Throughout my life and career, I've been fortunate to have access to the best medical professionals, nutrition experts, and fitness coaches. Their guidance has been crucial to my health and well-being. That's why I am excited to be working with Prenetics—a company dedicated to innovative, world-leading scientific advancements in health—as a co-founding partner and ambassador for IM8."
貝克漢姆表示：“在我的生活和職業生涯中，我有幸接觸到最好的醫務人員、營養專家和健身教練。他們的指導對我的健康和幸福至關重要。這就是爲什麼我很高興能與Prenetics合作——這是一家致力於創新、在健康領域引領世界的科學進步的公司——作爲IM8的共同創始夥伴和大使。”
Prenetics is a health sciences company. IM8, a new health and wellness brand, leads consumer initiatives.
Prenetics是一家健康科學公司。IM8是一家新的健康和保健品牌，主導消費者倡議。
The clinical division is led by Insighta, a $200 million joint venture with renowned scientist Prof. Dennis Lo, focused on multi-cancer early detection technologies.
臨床部門由Insighta領導，後者是與著名科學家盧松霖教授聯合創辦的200 million美元的合資企業，專注於多癌種早期檢測技術。
Prenetics reported first-quarter revenue of $6.4 million, an increase of 30.2% compared to the first quarter of 2023.
Prenetics報告第一季度營業收入640萬美元，同比增長30.2%，相比2023年第一季度有所增長。
Danny Yeung, CEO and Co-Founder of Prenetics, remarked: "The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit...Our purpose remains dedicated to our science-first approach in our pivot to consumer healthcare to broaden accessibility to science-based health and wellness."
Prenetics的CEO兼聯合創始人Danny Yeung說：“2024年第一季度是我們公司的良好開端，展示出營收和毛利潤實現了穩健增長......我們的目標仍然是始終堅持科學爲本的理念，在我們轉向消費者醫療保健領域，通過廣泛開展以科學爲基礎的健康和保健活動來提高健康資源的可達性。”
The company reported cash and other short-term assets of $86.6 million as of March 31, 2024.
該公司截至2024年3月31日的現金和其他短期資產爲8,660萬美元。
Price Action: PRE shares are up 1.01% at $6.06 at the last check on Thursday.
股票價格表現：PRE股票在週四最後一次覈查時上漲1.01%，至6.06美元。
- EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
- 獨家：Vivani醫療概述計劃，今年啓動第一項微型GLP-1肥胖植入治療方案的臨床研究。
Photo via Shutterstock
圖片來自shutterstock。